share_log

Cooper Companies | 8-K: CooperCompanies Announces Third Quarter 2024 Results

Cooper Companies | 8-K: CooperCompanies Announces Third Quarter 2024 Results

庫珀醫療 | 8-K：庫珀公司公佈2024年第三季度業績
美股SEC公告 ·  2024/08/29 04:23

Moomoo AI 已提取核心訊息

Cooper Companies reported strong Q3 FY2024 results with revenue increasing 8% YoY to $1,002.8 million. CooperVision revenue grew 7% to $675.6 million, while CooperSurgical revenue rose 9% to $327.2 million. GAAP diluted EPS increased 22% to $0.52, and non-GAAP diluted EPS grew 14% to $0.96.Operating performance showed improvement with non-GAAP operating margin expanding to 26% from 24% last year, driven by gross margin gains and SG&A leverage. The company generated free cash flow of $118.5 million after capital expenditures of $89.0 million.Based on strong performance, Cooper raised its fiscal 2024 guidance, now projecting total revenue of $3,892-$3,913 million with 8-8.5% organic growth. The company expects non-GAAP diluted EPS of $3.64-$3.67 for the full year, demonstrating continued momentum in its growth strategy.
Cooper Companies reported strong Q3 FY2024 results with revenue increasing 8% YoY to $1,002.8 million. CooperVision revenue grew 7% to $675.6 million, while CooperSurgical revenue rose 9% to $327.2 million. GAAP diluted EPS increased 22% to $0.52, and non-GAAP diluted EPS grew 14% to $0.96.Operating performance showed improvement with non-GAAP operating margin expanding to 26% from 24% last year, driven by gross margin gains and SG&A leverage. The company generated free cash flow of $118.5 million after capital expenditures of $89.0 million.Based on strong performance, Cooper raised its fiscal 2024 guidance, now projecting total revenue of $3,892-$3,913 million with 8-8.5% organic growth. The company expects non-GAAP diluted EPS of $3.64-$3.67 for the full year, demonstrating continued momentum in its growth strategy.
庫珀醫療發佈了2024財年第三季度的強勁業績，營業收入同比增長8%，達到100280萬美元。庫珀視覺的營業收入增長7%，達到67560萬美元，而庫珀外科的營業收入上升9%，達到32720萬美元。根據GAAP，攤薄後每股收益增加22%，達到0.52美元，非GAAP攤薄後每股收益增長14%，達到0.96美元。運營表現有所改善，非GAAP營業利潤率從去年的24%擴大到26%，這得益於毛利率的提升和銷售及管理費用的槓桿作用。公司在8900萬美元的資本支出後，產生了11850萬美元的自由現金流。基於良好的業績，庫珀上調了2024財年的指導預期，現在預計總營業收入在3892萬到391300萬美元之間，預期有8%到8.5%的有機增長。公司預計全年的非GAAP攤薄後每股收益爲3.64美元到3.67美元，顯示出其增長策略的持續勢頭。
庫珀醫療發佈了2024財年第三季度的強勁業績，營業收入同比增長8%，達到100280萬美元。庫珀視覺的營業收入增長7%，達到67560萬美元，而庫珀外科的營業收入上升9%，達到32720萬美元。根據GAAP，攤薄後每股收益增加22%，達到0.52美元，非GAAP攤薄後每股收益增長14%，達到0.96美元。運營表現有所改善，非GAAP營業利潤率從去年的24%擴大到26%，這得益於毛利率的提升和銷售及管理費用的槓桿作用。公司在8900萬美元的資本支出後，產生了11850萬美元的自由現金流。基於良好的業績，庫珀上調了2024財年的指導預期，現在預計總營業收入在3892萬到391300萬美元之間，預期有8%到8.5%的有機增長。公司預計全年的非GAAP攤薄後每股收益爲3.64美元到3.67美元，顯示出其增長策略的持續勢頭。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Kestra Medical Technologies
    KMTS
    -- 24.920
    中進醫療
    ZJYL
    -- 0.743
    Predictive Oncology
    POAI
    -- 1.5200
    Embecta
    EMBC
    -- 12.750
    NexGel
    NXGL
    -- 2.980
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點